Barclays Reiterates Overweight Rating on Iovance Biotherapeutics, Inc. (IOVA)

Market Context

Iovance Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $8.04 with a market capitalization of $744.6M. The stock has gained 344.2% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Iovance Biotherapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Iovance Biotherapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 06, 2026	Citizens	Market Outperform	N/A
Nov 06, 2026	Barclays	Overweight	N/A
Nov 03, 2026	UBS	Neutral	N/A
Oct 13, 2026	Barclays	Overweight	N/A
Oct 08, 2026	Baird	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View IOVA Stock Page